Content about Anti-diabetic medication

November 25, 2013

Federal regulators are lifting some restrictions on a diabetes drug that were placed two years ago after studies linked the drug to increased cardiovascular risk.

SILVER SPRINGS, Md. – Federal regulators are lifting some restrictions on a diabetes drug that were placed two years ago after studies linked the drug to increased cardiovascular risk.

October 23, 2013

Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

NEWARK, Calif. — Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

The drug maker announced that it had sold its interest in the Type 2 diabetes therapeutic area to PDL for $240.5 million, which it plans to use to acquire rights to products it said would drive long-term growth and build on its expertise in pain and neurology.

September 10, 2013

Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

NEWARK, Calif. — Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

The licensing agreement, which the two companies entered in July 2009, gives Merck a non-exclusive license and other rights to certain Depomed patents for extended-release metformin, while Depomed will receive "modest" royalties on net product sales of the drug Janumet XR (sitagliptin; metformin hydrochloride) in countries in which the licensed patents cover the product.

July 30, 2013

Some patients with Type 2 diabetes taking drugs to lower blood sugar may experience a greater drop than is healthy for them even though their disease may not be under control, according to a new study.

OAKLAND, Calif. — Some patients with Type 2 diabetes taking drugs to lower blood sugar may experience a greater drop than is healthy for them even though their disease may not be under control, according to a new study.

June 19, 2013

Three new drugs for Type 2 diabetes made by Takeda Pharmaceutical have become available in pharmacies, the company said.

DEERFIELD, Ill. — Three new drugs for Type 2 diabetes made by Takeda Pharmaceutical Co. have become available in pharmacies, the company said.

The drug maker announced the availability of Nesina (alogliptin), Kazano (alogliptin; metformin hydrochloride) and Oseni (alogliptin; pioglitazone).

June 10, 2013

A 26-member joint panel comprising the Food and Drug Administration's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted to support modifying or removing the risk evaluation and mitigation strategy protocol for GlaxoSmithKline's Type 2 diabetes drug Avandia (rosiglitazone).

Historically, the FDA has followed advisory committee votes when making a decision on the marketing of a drug even though it is not bound by them, but assuming the agency follows the panel's advice, it could mean a lot for the controversial drug and the way it's dispensed. But even if Avandia winds up on retail pharmacy shelves again, it faces a very different landscape from its heyday.

A 26-member joint panel comprising the Food and Drug Administration's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted to support modifying or removing the risk evaluation and mitigation strategy protocol for GlaxoSmithKline's Type 2 diabetes drug Avandia (rosiglitazone).

June 7, 2013

A joint Food and Drug Administration expert panel voted to recommend keeping a controversial GlaxoSmithKline diabetes drug available for certain patients, GSK said.

PHILADELPHIA — A joint Food and Drug Administration expert panel voted to recommend keeping a controversial GlaxoSmithKline diabetes drug available for certain patients, GSK said.

April 19, 2013

The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

MUMBAI, India — The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

Sun announced the tentative approvals for sitagliptin tablets in the 25 mg, 50 mg and 100 mg strengths and metformin hydrochloride extended-release tablets in the 500 mg and 1,000 mg strengths. The drugs are respectively generic versions of Merck's Januvia and Santarus' Glumetza.

October 19, 2012

Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.

MILPITAS, Calif. — Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.